Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1333
Peer-review started: October 7, 2021
First decision: December 2, 2021
Revised: January 30, 2022
Accepted: June 13, 2022
Article in press: June 13, 2022
Published online: July 27, 2022
Processing time: 293 Days and 0.5 Hours
The global burden of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and coinfection represents a major public health concern, particularly in resource-limited settings. Elimination of HCV by 2030 has become foreseeable, with effective direct-acting antiviral oral therapies and the availability of affordable generics in low-and-middle-income countries (LMICs). However, access to oral nucleos(t)ide therapy for HBV remains critical and is limited outside the existing global HIV program platforms despite affordable prices. Prevention of mother-to-child transmission of HBV through scaling up of birth dose implementation in LMICs is essential to achieve the 2030 elimination goal. Most individuals living with HBV and/or HCV in resource-limited settings are unaware of their infection, and with improved access to medications, the most significant barrier remains access to affordable diagnostics and preventive strat
Core Tip: This minireview presents the data and challenges associated with hepatitis B virus (HBV) and hepatitis C virus (HCV)/coinfection in resource-limited settings. It also underlines the key gaps and strategies for elimination of HBV and HCV infections in the low and middle-income countries. Global efforts should continue to improve awareness and political commitment. Equally important is securing financial resources for access and implementation of comprehensive strategies for diagnosis and linkage to care in resource-constrained settings to fulfill the 2030 elimination goal.
